Global Information
회사소개 | 문의 | 비교리스트

세계의 신장병 치료제 시장 기회 분석 및 산업 예측(2021-2030년) : 약제 클래스, 투여 경로, 유통경로별

Nephrology Drugs Market by Drug Class, Route of Administration, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2030

리서치사 Allied Market Research
발행일 2021년 12월 상품코드 1059629
페이지 정보 영문 267 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 4,125 ₩ 5,256,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 6,168 ₩ 7,859,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,929 ₩ 8,828,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,663 ₩ 13,586,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 신장병 치료제 시장 기회 분석 및 산업 예측(2021-2030년) : 약제 클래스, 투여 경로, 유통경로별 Nephrology Drugs Market by Drug Class, Route of Administration, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2030
발행일 : 2021년 12월 페이지 정보 : 영문 267 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 신장병 치료제 시장 규모는 2020년 145억 175만 달러에서 예측기간에는 5.0%의 연평균 복합 성장률(CAGR)로 확대되어 2030년까지 234억 542만 달러 규모로 성장할 것으로 예측됩니다.

신장병에 대한 인식 향상과 발병률 상승, 라이프스타일 변화, 당뇨병과 고혈압 환자 증가 등의 요인이 시장 성장의 원동력이 되고 있습니다. 만성 신장병과 급성 신장병 등의 질환은 신장내과 치료제로 치료할 수 있기 때문에 시장 성장에 크게 기여하고 있습니다. 신장병에 대한 의식 고양, R&D 및 혁신에 대한 투자 증가 또한 세계 시장 성장을 뒷받침하고 있습니다.

세계의 신장병 치료제(Nephrology Drugs) 시장을 조사했으며, 시장의 정의와 개요, 시장 영향요인 분석, 시장 규모 추이와 예측, 약제 클래스·투여 경로·유통경로·지역/주요 국가 등 각종 구분별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 개요

제3장 시장 구도

  • 시장의 정의와 범위
  • 주요 조사 결과
  • Porter의 산업 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
  • COVID-19 : 영향 분석

제4장 신장병 치료제 시장 : 약제 클래스별

  • 개요
  • ACE 억제제
  • 칼슘 채널 차단제
  • 베타 차단제
  • 이뇨제
  • 기타
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제5장 신장병 치료제 시장 : 투여 경로별

  • 개요
  • 경구
  • 비경구
  • 기타
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제6장 신장병 치료제 시장 : 유통경로별

  • 개요
  • 병원 약국
  • 소매 약국
  • 온라인 약국
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제7장 신장병 치료제 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카, 중동 및 아프리카
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모와 예측 : 국가별
    • 시장 규모와 예측 : 약제 클래스별
    • 시장 규모와 예측 : 투여 경로별
    • 시장 규모와 예측 : 유통경로별

제8장 기업 개요

  • AstraZeneca PLC.
  • Pfizer, Inc.
  • Amgen Inc.
  • FibroGen Inc.
  • GlaxoSmithKline PLC.
  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Teva Pharmaceutical Industries Limited.
  • Johnson and Johnson
  • F. HOFFMANN-LA ROCHE LTD.
LSH 22.03.10

LIST OF TABLES

  • TABLE 01.NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 02.NEPHROLOGY DRUGS MARKET FOR ACE INHIBITORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.NEPHROLOGY DRUGS MARKET FOR CALCIUM CHANNEL BLOCKER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.NEPHROLOGY DRUGS MARKET FOR BETA BLOCKERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.NEPHROLOGY DRUGS MARKET FOR DIURETICS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.NEPHROLOGY DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 08.NEPHROLOGY DRUGS MARKET FOR ORAL, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.NEPHROLOGY DRUGS MARKET FOR PARENTERAL, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.NEPHROLOGY DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 12.NEPHROLOGY DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.NEPHROLOGY DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.NEPHROLOGY DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.NEPHROLOGY DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.NORTH AMERICA NEPHROLOGY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 17.U.S. NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 18.U.S. NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 19.U.S. NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 20.CANADA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 21.CANADA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 22.CANADA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 23.MEXICO NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 24.MEXICO NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 25.MEXICO NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 26.NORTH AMERICA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 27.NORTH AMERICA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 28.NORTH AMERICA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 29.EUROPE NEPHROLOGY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 30.GERMANY NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 31.GERMANY NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 32.GERMANY NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 33.FRANCE NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 34.FRANCE NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 35.FRANCE NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 36.UK NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 37.UK NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 38.UK NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 39.ITALY NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 40.ITALY NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 41.ITALY NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 42.SPAIN NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 43.SPAIN NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 44.SPAIN NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 45.REST OF EUROPE NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 46.REST OF EUROPE NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 47.REST OF EUROPE NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 48.EUROPE NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 49.EUROPE NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 50.EUROPE NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 51.ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 52.JAPAN NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 53.JAPAN NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 54.JAPAN NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 55.CHINA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 56.CHINA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 57.CHINA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 58.AUSTRALIA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 59.AUSTRALIA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 60.AUSTRALIA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 61.INDIA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 62.INDIA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 63.INDIA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 64.REST OF ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 65.REST OF ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 66.REST OF ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 67.ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 68.ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 69.ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 70.LAMEA NEPHROLOGY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 71.BRAZIL NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 72.BRAZIL NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 73.BRAZIL NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 74.SAUDI ARABIA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 75.SAUDI ARABIA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 76.SAUDI ARABIA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 77.SOUTH AFRICA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 78.SOUTH AFRICA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 79.SOUTH AFRICA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 80.REST OF LAMEA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 81.REST OF LAMEA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 82.REST OF LAMEA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 83.LAMEA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
  • TABLE 84.LAMEA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 85.LAMEA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 86.ASTRAZENECA PLC.: COMPANY SNAPSHOT
  • TABLE 87.ASTRAZENECA PLC.: OPERATING SEGMENTS
  • TABLE 88.ASTRAZENECA PLC.: PRODUCT PORTFOLIO
  • TABLE 89.ASTRAZENECA PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 91.PFIZER: OPERATING SEGMENTS
  • TABLE 92.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 93.PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94.AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 95.AMGEN INC.: OPERATING SEGMENTS
  • TABLE 96.AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 97.FIBROGEN, INC.: COMPANY SNAPSHOT
  • TABLE 98.FIBROGEN, INC.: OPERATING SEGMENTS
  • TABLE 99.FIBROGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 100.FIBROGEN, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 102.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 103.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 104.GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 106.ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 107.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 108.AKEBIA THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 109.AKEBIA THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 110.AKEBIA THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 111.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: COMPANY SNAPSHOT
  • TABLE 112.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: OPERATING SEGMENTS
  • TABLE 113.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 114.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115.J&J: COMPANY SNAPSHOT
  • TABLE 116.J&J: OPERATING BUSINESS SEGMENTS
  • TABLE 117.J&J: PRODUCT PORTFOLIO
  • TABLE 118.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 119.F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 120.F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.NEPHROLOGY DRUGS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS IN NEPHROLOGY DRUGS MARKET, 2020
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019-2021*
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021*
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
  • FIGURE 01.LOW-MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 02.HIGH BARGAINING POWER OF BUYERS
  • FIGURE 03.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 05.HIGH INTENSITY OF COMPETITIVE RIVALRY
  • FIGURE 06.TOP PLAYER POSITIONING, 2020
  • FIGURE 07.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR ACE INHIBITORS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 08.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR CALCIUM CHANNEL BLOCKER, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 09.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR BETA BLOCKERS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 10.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR DIURETICS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 11.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 12.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR ORAL, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 13.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR CALCIUM CHANNEL BLOCKER, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 18.ASTRAZENECA PLC.: NET SALES, 2018-2020 ($ MILLION)
  • FIGURE 19.ASTRAZENECA PLC.: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 20.ASTRAZENECA PLC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 21.PFIZER INC.: NET SALES, 2018-2020 ($ MILLION)
  • FIGURE 22.PFIZER INC.: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 23.PFIZER INC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 24.AMGEN INC.: NET SALES, 2018-2020 ($ MILLION)
  • FIGURE 25.AMGEN INC.: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 26.FIBROGEN, INC.NET SALES, 2018-2020 ($ MILLION)
  • FIGURE 27.FIBROGEN, INC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 28.GLAXOSMITHKLINE PLC.: NET SALES, 2018-2020 ($ MILLION)
  • FIGURE 29.GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 30.GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 31.ABBVIE INC: NET SALES, 2018-2020 ($ MILLION)
  • FIGURE 32.ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 33.ABBVIE INC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 34.AKEBIA THERAPEUTICS, INC.: NET SALES, 2018-2020 ($ MILLION)
  • FIGURE 35.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, 2018-2020 ($ MILLION)
  • FIGURE 36.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 37.J&J: NET SALES, 2018-2020 ($ MILLION)
  • FIGURE 38.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 39.J&J: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 40.F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2018-2020 ($ MILLION)
  • FIGURE 41.F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 42.F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2020 (%)

The global nephrology drugs market was valued at $14,501.75 million in 2020, and is projected to reach $23,405.42 million by 2030, registering a CAGR of 5.0% from 2021 to 2030.

Nephrology deals with diagnosis and the treatment related to kidney disorders as well as involves the management of kidney functioning. It further consists of other renal replacement therapies such as dialysis and kidney transplantation. Diabetes, hypertension, electrolytes disturbances, and autoimmune diseases are treated. Along with this, other diseases include acute kidney injury, hematuria, chronic kidney disease, proteinuria, disorders of electrolytes or acid/base, and kidney stones.

The factors that drive the growth of the global nephrology drugs market include rise in awareness & incidence of kidney diseases, changes in lifestyle, and rise in cases of diabetes & hypertension. Disorders such as chronic kidney disease and acute kidney diseases can be treated by nephrology drugs, which notably contributes toward the market growth. In addition, rise in awareness pertaining to kidney diseases and increase in investment in research, development, and innovation supplement the market growth, globally.

The nephrology drugs market is segmented into drug class, route of administration, distribution channel, and region. By drug class, the market is classified into ACE inhibitors, calcium channel blocker, beta blockers, diuretics, and others. Depending on route of administration, it is categorized into oral, parenteral, and others. On the basis of distribution channel, it is segregated into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major factors driving the growth of the nephrology drugs market are alarming rise in cases of kidney failures, surge in prevalence of various chronic nephrology diseases, adoption of unhealthy lifestyle, and rise in geriatric population. In addition, increase in alcohol consumption, rise in the number of diagnostic tests for kidney diseases, surge in obese population, rise in R&D activities for launch of novel drugs and improvement in the existing drugs, and emerging technology in developing economies are positively impacting the growth of the nephrology drugs market.

However, the cost of treatment for kidney disorders is high, which is expected to create hindrances for the growth of the nephrology drugs market. Moreover, lack of awareness in general population and low alertness about suffering from kidney diseases, and there has been an inclination of generic drugs are causing hurdles in the nephrology drugs market.

Various initiatives have been taken by the government to encourage the regulatory affairs in getting approvals for novel drugs, and insurance policies which are creating lucrative opportunities in the nephrology drugs market.

Region wise, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the nephrology drugs market in 2020, and is expected to retain its dominance throughout the forecast period. This is primarily attributed to the awareness regarding the chronic kidney diseases in this region. Moreover, rise in investments by key players in this region contributes toward the market growth.

Business expansions is the key strategy adopted by market players. The report provides a comprehensive analysis of the key players that operate in the global nephrology drugs market. The key companies profiled in the report include AstraZeneca, AbbVie Inc., Akebia Therapeutics, Inc., Amgen Inc., F. Hoffmann-La Roche, FibroGen Inc., GlaxoSmithkline PLC., Johnson & Johnson Inc., Pfizer Inc., and Teva Pharmaceutical Industries Limited.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides in-depth analysis of the global nephrology drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global nephrology drugs market growth.

KEY MARKET SEGMENTS

By Drug Class

  • ACE inhibitors
  • Calcium channel blockers
  • Beta Blockers
  • Diuretics
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

List of key players profiled in the report:

  • AstraZeneca
  • Pfizer Inc.
  • Amgen Inc.
  • FibroGen Inc.
  • GlaxoSmithkline plc.
  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Teva Pharmaceutical Industries,
  • Johnson & Johnson Inc.
  • F. Hoffmann-La Roche.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increasing incidence of chronic kidney diseases
      • 3.5.1.2.Technological Advancements in developing countries
      • 3.5.1.3.Rising Investment by Key Players
    • 3.5.2.Restraint
      • 3.5.2.1.High treatment cost and lack of awareness for Chronic Kidney Diseases
    • 3.5.3.Opportunities
      • 3.5.3.1.Initiatives by Governments for regulatory approvals
  • 3.6.Covid-19 Impact analysis on Nephrology Drugs market

CHAPTER 4:NEPHROLOGY MARKET, BY DRUG CLASS

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.ACE inhibitors
    • 4.2.1.Market size and forecast, by region
    • 4.2.2.Market analysis, by country
  • 4.3.Calcium Channel Blocker
    • 4.3.1.Market size and forecast, by region
    • 4.3.2.Market analysis, by country
  • 4.4.Beta Blockers
    • 4.4.1.Market size and forecast, by region
    • 4.4.2.Market analysis, by country
  • 4.5.Diuretics
    • 4.5.1.Market size and forecast, by region
    • 4.5.2.Market analysis, by country
  • 4.6.Others
    • 4.6.1.Market size and forecast, by region
    • 4.6.2.Market analysis, by country

CHAPTER 5:NEPHROLOGY MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Oral
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Parenteral
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Others
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country

CHAPTER 6:NEPHROLOGY MARKET, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospital Pharmacy
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Retail Pharmacy
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Online Pharmacy
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country

CHAPTER 7:NEPHROLOGY DRUGS MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
      • 7.2.2.1.U.S.
      • 7.2.2.1.1.U.S. Nephrology drugs market, by drug class
      • 7.2.2.1.2.U.S. Nephrology drugs market, by route of administration
      • 7.2.2.1.3.U.S. Nephrology drugs market, by distribution channel
      • 7.2.2.2.Canada
      • 7.2.2.2.1.Canada Nephrology drugs market, by drug class
      • 7.2.2.2.2.Canada Nephrology drugs market, by route of administration
      • 7.2.2.2.3.Canada Nephrology drugs market, by distribution channel
      • 7.2.2.3.Mexico
      • 7.2.2.3.1.Mexico Nephrology drugs market, by drug class
      • 7.2.2.3.2.Mexico Nephrology drugs market, by route of administration
      • 7.2.2.3.3.Mexico Nephrology drugs market, by distribution channel
    • 7.2.3.North America market size and forecast, by drug class
    • 7.2.4.North America market size and forecast, by route of administration
    • 7.2.5.North America market size and forecast, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Germany Nephrology drugs market, by drug class
      • 7.3.2.1.2.Germany Nephrology drugs market, by route of administration
      • 7.3.2.1.3.Germany Nephrology drugs market, by distribution channel
      • 7.3.2.2.France
      • 7.3.2.2.1.France Nephrology drugs market, by drug class
      • 7.3.2.2.2.France Nephrology drugs market, by route of administration
      • 7.3.2.2.3.France Nephrology drugs market, by distribution channel
      • 7.3.2.3.UK
      • 7.3.2.3.1.UK Nephrology drugs market, by drug class
      • 7.3.2.3.2.UK Nephrology drugs market, by route of administration
      • 7.3.2.3.3.UK Nephrology drugs market, by distribution channel
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Italy Nephrology drugs market, by drug class
      • 7.3.2.4.2.Italy Nephrology drugs market, by route of administration
      • 7.3.2.4.3.Italy Nephrology drugs market, by distribution channel
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Spain Nephrology drugs market, by drug class
      • 7.3.2.5.2.Spain Nephrology drugs market, by route of administration
      • 7.3.2.5.3.Spain Nephrology drugs market, by distribution channel
      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Rest of Europe Nephrology drugs market, by drug class
      • 7.3.2.6.2.Rest of Europe Nephrology drugs market, by route of administration
      • 7.3.2.6.3.Rest of Europe Nephrology drugs market, by distribution channel
    • 7.3.3.Europe market size and forecast, by drug class
    • 7.3.4.Europe market size and forecast, by route of administration
    • 7.3.5.Europe market size and forecast, by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
      • 7.4.2.1.Japan
      • 7.4.2.1.1.Japan Nephrology drugs market, by drug class
      • 7.4.2.1.2.Japan Nephrology drugs market, by route of administration
      • 7.4.2.1.3.Japan Nephrology drugs market, by distribution channel
      • 7.4.2.2.China
      • 7.4.2.2.1.China Nephrology drugs market, by drug class
      • 7.4.2.2.2.China Nephrology drugs market, by route of administration
      • 7.4.2.2.3.China Nephrology drugs market, by distribution channel
      • 7.4.2.3.Australia
      • 7.4.2.3.1.Australia Nephrology drugs market, by drug class
      • 7.4.2.3.2.Australia Nephrology drugs market, by route of administration
      • 7.4.2.3.3.Australia Nephrology drugs market, by distribution channel
      • 7.4.2.4.India
      • 7.4.2.4.1.India Nephrology drugs market, by drug class
      • 7.4.2.4.2.India Nephrology drugs market, by route of administration
      • 7.4.2.4.3.India Nephrology drugs market, by distribution channel
      • 7.4.2.5.Rest of Asia-Pacific
      • 7.4.2.5.1.Rest of Asia-Pacific Nephrology drugs market, by drug class
      • 7.4.2.5.2.Rest of Asia-Pacific Nephrology drugs market, by route of administration
      • 7.4.2.5.3.Rest of Asia-Pacific Nephrology drugs market, by distribution channel
    • 7.4.3.Asia-Pacific market size and forecast, by drug class
    • 7.4.4.Asia-Pacific market size and forecast, by route of administration
    • 7.4.5.Asia-Pacific market size and forecast, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
      • 7.5.2.1.Brazil
      • 7.5.2.1.1.Brazil Nephrology drugs market, by drug class
      • 7.5.2.1.2.Brazil Nephrology drugs market, by route of administration
      • 7.5.2.1.3.Brazil Nephrology drugs market, by distribution channel
      • 7.5.2.2.Saudi Arabia
      • 7.5.2.2.1.Saudi Arabia Nephrology drugs market, by drug class
      • 7.5.2.2.2.Saudi Arabia Nephrology drugs market, by route of administration
      • 7.5.2.2.3.Saudi Arabia Nephrology drugs market, by distribution channel
      • 7.5.2.3.South Africa
      • 7.5.2.3.1.South Africa Nephrology drugs market, by drug class
      • 7.5.2.3.2.South Africa Nephrology drugs market, by route of administration
      • 7.5.2.3.3.South Africa Nephrology drugs market, by distribution channel
      • 7.5.2.4.Rest of LAMEA
      • 7.5.2.4.1.Rest of LAMEA Nephrology drugs market, by drug class
      • 7.5.2.4.2.Rest of LAMEA Nephrology drugs market, by route of administration
      • 7.5.2.4.3.Rest of LAMEA Nephrology drugs market, by distribution channel
    • 7.5.3.LAMEA market size and forecast, by drug class
    • 7.5.4.LAMEA market size and forecast, by route of administration
    • 7.5.5.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.AstraZeneca PLC.
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.Pfizer, Inc.
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
    • 8.2.6.Key strategic moves and developments
  • 8.3.Amgen Inc.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.FibroGen Inc.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.GlaxoSmithKline PLC.
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.AbbVie Inc.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
  • 8.7.Akebia Therapeutics, Inc.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.Teva Pharmaceutical Industries Limited.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.Johnson and Johnson
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.F. HOFFMANN-LA ROCHE LTD.
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
Back to Top
전화 문의
F A Q